National Psoriasis Foundation


National Psoriasis Foundation awards nearly half a million dollars in medical research fellowships

Twelve early-career doctors each received a one-year, $40,000 medical research fellowship from the National Psoriasis Foundation (NPF) to study psoriasis and psoriatic arthritis. The fellowships are designed to increase the number of physician researchers investigating psoriatic diseases—leading to more discoveries, better treatments and, ultimately, a cure.

The current NPF Medical Research Fellows and their projects are:

  • Shehla Admani, M.D., of Rady Children's Hospital/University of California, San Diego School of Medicine, will study the occurrence of non-alcoholic fatty liver disease (NAFLD) in pediatric psoriasis to determine the relationship between psoriasis, liver disease and obesity in children.
  • Neil Borkar, M.D., of Baylor Institute for Immunology Research in Dallas, will profile genes and study T cells, involved in inflammation, before and after treatment with IL-12/IL-23 blockers.
  • Sarah Churton, M.D., of University Hospitals of Cleveland and Case Medical Center in Cleveland, Ohio, will evaluate the efficacy of different systemic agents to treat psoriasis and study their effects on cardiovascular risk factors.
  • Rosemary DeShazo, M.D., of the University of Utah in Salt Lake City, will explore the effectiveness of biologic drugs when compared with and without use of methotrexate. DeShazo will also design a study to evaluate if patients' treatment satisfaction correlates with the initiation of treatment changes by a physician.
  • Lorraine Jennings, M.D., of Massachusetts General Hospital and Harvard University Medical School in Boston, will assess the impact of obesity and psoriasis on quality of life and socioeconomic outcomes.
  • Noori Kim, M.D., of Tufts Medical Center in Boston, will study the differences in baseline characteristics of patients with psoriatic arthritis (PsA) in recent clinical trials for Simponi (golimumab) and Remicade (infliximab) to show that these differences predict varying treatment outcomes.
  • Ethan Levin, M.D., of the University of California, San Francisco, will document the negative psychosocial impact of psoriasis and track how it improves with certain therapies. Levin will also study the efficacy of combined excimer laser and topical treatment for psoriasis.
  • Shaowei Wu, M.D., of Brigham and Women's Hospital at Harvard Medical School in Boston, aims to investigate bone health in patients with psoriasis to examine potential biomarkers in psoriasis and psoriatic arthritis.
  • Steven Nwe, D.O., of The Feinberg School of Medicine at Northwestern University in Evanston, Ill., will establish a registry to examine patient responses relating to treatment of psoriatic diseases in a real-world setting.
  • Shelbi Jim On, M.D., of Mt. Sinai School of Medicine in New York City, will focus on several psoriasis clinical trials to test the efficacy and safety of potential treatments.
  • Junko Takeshita M.D., of the University of Pennsylvania Perelman School of Medicine in Philadelphia, will investigate the serious infection risk in patients with psoriasis, as well as evaluate the effect of psoriasis treatments on heart disease.
  • Cameron West, M.D., of Wake Forest University School of Medicine in Winston-Salem, N.C., will focus on using technology such as Internet surveys to improve adherence to psoriasis treatment.

May 14, 2012

National Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.